Zobrazeno 1 - 10
of 645
pro vyhledávání: '"H Kaffarnik"'
Publikováno v:
Journal of Lipid Research, Vol 35, Iss 1, Pp 153-158 (1994)
The influence of the genetic apolipoprotein (apo) E isoforms on human plasma lipoproteins is well established. There is, however, still a need for a phenotyping procedure applicable in laboratories not specialized in lipid research. To this end, we d
Externí odkaz:
https://doaj.org/article/7c77ebf4ce6244a78bff75b242d6068f
Publikováno v:
Journal of Lipid Research, Vol 31, Iss 6, Pp 1005-1013 (1990)
A family with three heterozygote and two homozygote carriers of the rare apolipoprotein E1 isoform was detected by isoelectric focusing. One of the homozygous patients had type III hyperlipidemia, while the other showed normolipemic dysbetalipoprotei
Externí odkaz:
https://doaj.org/article/6c47c6cbfce04444813dc4219f31f6c6
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 120:325-328
A now 24-year-old woman was found at the age of 2 years to have an hyperchylomicronaemia syndrome due to lipoprotein lipase deficiency: the triglyceride level was then 6000 mg/dl. But in subsequent years it had been reduced to between 550 and 2600 mg
Autor:
K. Ehlenz, C. Baerwald, Armin Steinmetz, H. Kaffarnik, C. Pilz, J. R. Schafer, P. von Wichert, D. H. Hunneman
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 119:327-331
Adrenomyeloneuropathy (AMN) is a "milder form" of adrenoleukodystrophy with a X-linked inheritance. Abnormal catabolism of the very long-chain fatty acids (VLCFA) results in Addison's disease and spastic paraparesis. The VLCFA concentration was measu
Autor:
Bernhard Maisch, H. Kaffarnik, H.J. Seyberth, Armin Steinmetz, Horst Schweer, J. R. Schaefer, Katsunori Ikewaki, H. Stracke
Publikováno v:
Atherosclerosis. 144:177-184
HMG-CoA reductase inhibitors, such as pravastatin, are widely used as lipid lowering drugs in hypercholesterolemia. Pravastatin does not only reduce the atherogenic low density lipoprotein (LDL)-cholesterol, but is also increasing high density lipopr
Publikováno v:
Journal of Cardiovascular Pharmacology. 27:563-570
In 12 weeks of active treatment, we compared the efficacy and safety of a new (micronized) formulation of fenofibrate (F) (200 mg/day) with that of simvastatin (S) (20 mg/day), an inhibitor of hydroxy-methyl-glutaryl coenzyme A (HMG-CoA)-reductase. M
Publikováno v:
Pediatrics. 93:296-302
Apolipoprotein (apo)E polymorphism has been shown to be associated with different serum levels of cholesterol, apoB, and apoE. In clarifying the degree of influence of the apoE isoforms, investigations in an early stage of life are useful. The aim of
Publikováno v:
Journal of Lipid Research, Vol 35, Iss 1, Pp 153-158 (1994)
The influence of the genetic apolipoprotein (apo) E isoforms on human plasma lipoproteins is well established. There is, however, still a need for a phenotyping procedure applicable in laboratories not specialized in lipid research. To this end, we d
Autor:
N Assefbarkhi, C Eltze, Armin Steinmetz, A Pies, Harald Funke, Gerd Assmann, K. Ehlenz, H. Kaffarnik
Publikováno v:
Journal of Lipid Research, Vol 31, Iss 6, Pp 1005-1013 (1990)
A family with three heterozygote and two homozygote carriers of the rare apolipoprotein E1 isoform was detected by isoelectric focusing. One of the homozygous patients had type III hyperlipidemia, while the other showed normolipemic dysbetalipoprotei
Publikováno v:
Deutsche medizinische Wochenschrift (1946). 120(10)
A now 24-year-old woman was found at the age of 2 years to have an hyperchylomicronaemia syndrome due to lipoprotein lipase deficiency: the triglyceride level was then 6000 mg/dl. But in subsequent years it had been reduced to between 550 and 2600 mg